Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AGRYLIN vs SUTENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate,Advanced renal cell carcinoma (RCC),Adjuvant treatment of adult patients at high risk of recurrent RCC after nephrectomy,Progressive, well-differentiated pancreatic neuroendocrine tumors (p NET) in patients with unresectable locally advanced or metastatic disease
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Terminal elimination half-life of sunitinib is 40-60 hours; for its primary active metabolite (SU12662) it is 80-110 hours. Steady-state achieved by day 14.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily metabolized by CYP3A4; the major metabolite (N-desethyl sunitinib) is also active and is further metabolized by CYP3A4.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Renal: 16% of total radioactivity; Fecal: ~70% of total radioactivity (primarily as unchanged parent and metabolites).
82–88% bound to plasma proteins (primarily albumin).
95% bound to human plasma proteins (albumin and alpha-1-acid glycoprotein).
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Apparent volume of distribution (Vd/F) is approximately 2230 L (enterprise, not weight-adjusted). The Vd is large, indicating extensive extravascular distribution.
Oral: 65–80% (median 73%)
Oral bioavailability is approximately 40% (range 30-50%).
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No adjustment for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min); avoid use in severe impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Child-Pugh Class A: 50 mg daily; Class B: reduce to 37.5 mg daily; Class C: not recommended.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Not approved for pediatric use; no established weight-based dosing.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
No specific dose adjustment; monitor renal function and blood pressure more frequently due to increased sensitivity to adverse effects.
None
Hepatotoxicity: Severe, sometimes fatal hepatotoxicity has been observed. Monitor liver function tests before and during treatment. Interrupt or discontinue SUTENT and manage as appropriate.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hepatotoxicity: Monitor liver function tests before and during therapy; interrupt or discontinue for severe hepatotoxicity.,Cardiovascular events: Hypertension, QT prolongation, left ventricular dysfunction, including heart failure; monitor blood pressure and cardiac function.,Hemorrhage: Severe, sometimes fatal hemorrhagic events; monitor for signs and symptoms.,Thyroid dysfunction: Monitor thyroid function; manage with thyroid hormone replacement as needed.,Adrenal insufficiency: Reported; monitor for symptoms.,Proteinuria: Monitor urine protein; discontinue for nephrotic syndrome.,Wound healing complications: Withhold therapy for at least 24 days prior to elective surgery.,Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue if signs/symptoms occur.,Thrombotic microangiopathy (TMA): Reported; discontinue if TMA occurs.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
None known.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Avoid grapefruit and grapefruit juice during treatment. St. John's wort may reduce efficacy. No other significant interactions.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm delivery due to antiangiogenic effects. Avoid use in pregnancy.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No human data available; M/P ratio unknown. Sunitinib and its metabolites are excreted in rat milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 4 weeks after the last dose.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Given teratogenicity, use is not recommended. If unavoidable, consider reduced dose (e.g., 37.5 mg daily) with close monitoring, but safety and efficacy are not validated.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Monitor for hypertension and proteinuria; manage with antihypertensives. Check thyroid function before and during therapy due to risk of hypothyroidism. Monitor liver enzymes and cardiac function, especially in patients with pre-existing conditions. Dose adjustments needed for hepatic impairment (Child-Pugh Class C).
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
Take with or without food, but avoid grapefruit juice.,Report any signs of bleeding, unusual bruising, or fatigue.,Monitor blood pressure regularly and report high readings.,Watch for changes in skin color (yellowing or darkening) or nail changes.,Use effective contraception during treatment and for at least 4 weeks after stopping.,Avoid sun exposure; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AGRYLIN vs SUTENT, answered by our medical review team.
AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. SUTENT is a Tyrosine Kinase Inhibitor Antineoplastic that works by Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AGRYLIN and SUTENT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. The standard adult dose of SUTENT is: 50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AGRYLIN and SUTENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. SUTENT is classified as Category C. Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth rest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.